Clinical trials: Leishmaniasis, Cutaneous
Leishmaniasis, Cutaneous, Vector Borne Diseases
Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria
The aim of this study is to determine the efficacy of Mosquito Shield (spatial repellent) in reducing cutaneous leishmaniasis case incidence among internally displaced persons and sandfly density in temporary shelters and camp…
- Trial name
- NCT06917040
- Testing
- Spatial repellant emanator
- Where
- Syria
- Volunteers
- 18,404 people, healthy volunteers welcome
- Sponsor
- The Mentor Initiative
Post Kala Azar Dermal Leishmaniasis
Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL
A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard…
- Trial name
- NCT00982774
- Testing
- LEISH-F2 + MPL-SE vaccine
- Where
- Sudan
- Volunteers
- 42 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Leishmaniasis, Cutaneous
A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
This trial is designed to assess the therapeutic efficacy and safety of CHAd63-KH, a new candidate Leishmania vaccine, in patients with persistent PKDL.
- Trial name
- NCT03969134
- Testing
- ChAd63-KH
- Where
- Sudan
- Volunteers
- 86 people
- Sponsor
- University of York
Cutaneous Leishmaniases
Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan
This research studies the effect thermotherapy as treatment of Old World CL which is not invasive, non-toxic, and the short treatment. While the current standard treatment comprise daily painful injections with antimonials,
- Trial name
- HECT-CL (NCT03208543)
- Testing
- HECT-CL
- Where
- Pakistan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Medecins Sans Frontieres, Netherlands
Cutaneous Leishmaniasis
Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis
The purpose of this study is to determine whether low-dose pentavalent antimony is equally effective when compared to the standard-dose regimen in patients with cutaneous leishmaniasis.
- Trial name
- Lowdosesb (NCT00317980)
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University of Brasilia
Cutaneous Leishmaniasis, Scar
Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application
Primary Objectives: Assess whether CL (caused by Leishmaniasis major) lesions treated with WR279396 improved the cosmetic outcome compared with no treatment (natural healing)
- Trial name
- SCAR (NCT00490230)
- Testing
- WR 279396
- Where
- Tunisia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Cutaneous Leishmaniasis
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
Cutaneous leishmaniasis is endemic in the New World from approximately the US-Mexican border through Central America and the Northern part of South America down to the level of Rio de Janeiro.
- Trial name
- NCT01380314
- Testing
- Miltefosine + Imiquimod
- Where
- Bolivia
- Volunteers
- 60 people
- Sponsor
- Foundation Fader
Cutaneous Leishmaniasis
Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia
Outcomes of patients receiving SSG and Allopurinol combination have never been documented systematically in Ethiopia. Therefore, it is not known how effective this combination is.
- Trial name
- NCT04699383
- Testing
- Sodium Stibogluconate with allopurinol
- Where
- Ethiopia
- Volunteers
- 105 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis…
- Trial name
- NCT00233545
- Testing
- miltefosine, antimony
- Where
- Bolivia
- Volunteers
- 80 people
- Sponsor
- AB Foundation
Leishmaniasis, Cutaneous
Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).
- Trial name
- NCT01032382
- Testing
- WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream), Paromomycin Alone Cream (15% paromomycin topical cream)
- Where
- Peru
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Leishmaniasis
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
OBJECTIVE: Compare the efficacy and side effects of allopurinol versus glucantime versus allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.
- Trial name
- NCT00004755
- Testing
- allopurinol, glucantime
- Volunteers
- 375 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous Leishmaniasis
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
This study is to determine the effectiveness and safety of WR 279,396, a topical cream for the treatment of cutaneous leishmaniasis.
- Trial name
- NCT00703924
- Testing
- WR 279,396
- Where
- 2 sites in France, Tunisia
- Volunteers
- 92 people
- Sponsor
- U.S. Army Medical Research and Development Command
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Cutaneous Leishmaniasis
Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis
Current standard therapies with chemotherapy (CT) for Cutaneous Leishmaniasis (CL) are expensive, toxic/allergenic, frequently ineffective, burdensome, and often unavailable.
- Trial name
- HECT (NCT01277796)
- Testing
- Heat pack conduction-heat therapy
- Sponsor
- Universidad Peruana Cayetano Heredia
Cutaneous Leihmaniasis
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
MAMS4CL comprises a clinical trial with three embedded sub-studies designed to comprehensively evaluate the administered treatments and assess the impact of CL treatment on patients and the healthcare system.
- Trial name
- NCT07463040
- Testing
- Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin
- Where
- 3 sites in Ethiopia
- Volunteers
- 900 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Leishmaniasis, Cutaneous
Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis
Infections due to protozoa of the genus Leishmania are a major worldwide skin problem, with high endemicity in developing countries including Pakistan.
- Trial name
- NCT04841239
- Testing
- Herbal topical formulation
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Jinnah Sindh Medical University
Cutaneous Leishmaniasis
Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
Cutaneous leishmaniasis is a parasitic skin lesion caused by different species of Leishmania and transmitted by the bite of infected sand flies.
- Trial name
- NCT00351520
- Testing
- Miltefose
- Where
- Iran
- Volunteers
- 148 people
- Sponsor
- Tehran University of Medical Sciences
Cutaneous Leishmaniases
Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis
Introduction: Up to the present, have been few studies with pentamidine in the Americas; and there is no consensus regarding the dose used.
- Trial name
- NCT02919605
- Testing
- Single dose of Pentamidine, Two doses of Pentamidine, Three doses of Pentamidine
- Volunteers
- 159 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Post Kala Azar Dermal Leishmaniasis
Ivermectin Repurposed for the Treatment of PKDL
Background (brief): 1. Burden: Post-Kala-Azar Dermal Leishmaniasis (PKDL) commonly follows visceral leishmaniasis (VL) caused by Leishmania donovani.
- Trial name
- NCT07286604
- Testing
- Ivermectin 6 MG Oral Tablet (2 tablets)
- Where
- Bangladesh
- Volunteers
- 10 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex
Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb) to placebo for L braziliensis in Bolivia.
- Conditions
- Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex, Leishmaniasis, American, Leishmaniasis; American, Cutaneous
- Trial name
- NCT03096457
- Testing
- Paromomycin Sulfate, Pentamidine Isethionate
- Where
- 2 sites in Bolivia
- Volunteers
- 80 people
- Sponsor
- Fundacion Nacional de Dermatologia